CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Standard COVID-19 therapiesWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug648 Convalescent Plasma (CP) Wiki 1.00
drug795 Duodenal biopsy Wiki 1.00
drug2186 Saliva Wiki 1.00

Correlated MeSH Terms (3)

Name (Synonyms) Correlation
D017250 Caliciviridae Infections NIH 0.71
D003141 Communicable Diseases NIH 0.09
D007239 Infection NIH 0.06

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Convalescent Plasma to Optimize Treatment of COVID-19 Disease in Pediatric Patients: A Feasibility Study

COVID-19 is increasingly affecting children but convalescent plasma (CP) has not been adequately studied in children to date. The study will determine safety of convalescent plasma for pediatric patients with severe, or at high risk for severe, COVID-19 disease.

NCT04458363 COVID Biological: Convalescent Plasma (CP) Drug: Standard COVID-19 therapies

Primary Outcomes

Description: Safety of convalescent plasma for pediatric patients will be determined by capturing the grade 3-5 adverse events that are possible, probably or definitely related to the CP infusion, defined using the NCI Common Terminology Criteria for Adverse Events (CTCAE)

Measure: Number of grade 3-5 adverse events that are possible, probably or definitely related to the convalescent plasma (CP) infusion

Time: 28 days

Secondary Outcomes

Description: Change in percent of supplemental oxygen within 72 hours after infusion

Measure: Change in percent of supplemental oxygen

Time: Baseline, 72 hours after infusion

Description: Number of patients that required change in level of respiratory support such as nasal canula, non-invasive ventilation, mechanical ventilation, high frequency oscillator ventilation, and extracorporeal membrane oxygenation (ECMO)

Measure: Number of patients that required change in level of respiratory support

Time: Baseline, 72 hours after infusion

Description: Number of deaths

Measure: Mortality

Time: up to 1 year

Description: Length of ICU stay (days) will be recorded

Measure: Mean length of ICU stay (days)

Time: Up to 28 days

Description: Length of hospital stay (days) will be recorded

Measure: Mean length of hospital stay (days)

Time: Up to 28 days

Description: Length of ventilation (days) will be recorded

Measure: Mean length of ventilation (days)

Time: Up to 28 days

Description: Number of patients with progression to renal dysfunction and/or multisystem organ failure will be recorded

Measure: Number of patients with progression to renal dysfunction and/or multisystem organ failure

Time: up to 1 year

Description: Cytokine milieu will be assayed by Luminex

Measure: IL-6 level

Time: up to 28 days

Description: Cellular studies will be used for evaluation of anti-SARS CoV 2 specific T cells

Measure: Number of anti-SARS CoV 2 specific T cells

Time: up to 28 days

Description: Cellular studies will be used for evaluation of diversity of circulating T cells

Measure: Diversity of circulating T cells

Time: up to 28 days

Description: Antibody titers to SARS-CoV-2 evaluation will be performed in vivo

Measure: ARS-CoV-2 Antibody Titer

Time: up to 28 days

Description: Neutralizing antibodies are a type of virus specific antibody that not only bind virus but bind in a manner that prevents viral infection. Test will be will be performed in vivo.

Measure: SARS-CoV-2 Neutralizing Titer

Time: up to 28 days

No related HPO nodes (Using clinical trials)